Request Demo
Last update 24 Jul 2026
Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.
Last update 24 Jul 2026
Overview
Tags
Neoplasms
Respiratory Diseases
Digestive System Disorders
Small molecule drug
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTR20243176
多索茶碱片在健康受试者中空腹状态下的单剂量、随机、开放、四周期、完全重复交叉设计的生物等效性试验
[Translation] A single-dose, randomized, open-label, four-period, completely repeated crossover bioequivalence study of doxofylline tablets in healthy subjects under fasting conditions
CTR20243180
多索茶碱片在健康受试者中餐后状态下的单剂量、随机、开放、四周期、完全重复交叉设计的生物等效性试验
[Translation] A single-dose, randomized, open-label, four-period, completely repeated crossover bioequivalence study of doxofylline tablets in healthy volunteers in the postprandial state
CTR20262071
黑龙江福和制药集团股份有限公司持有的乌帕替尼缓释片（规格：15 mg）与AbbVie Deutschland GmbH & Co. KG的乌帕替尼缓释片（Rinvoq®/瑞福®，15 mg）在中国健康试验参与者中进行的随机、开放、单剂量、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性试验
[Translation] A randomized, open-label, single-dose, two-sequence, two-period, two-crossover bioequivalence study of utpatinib extended-release tablets (15 mg) owned by Heilongjiang Fuhe Pharmaceutical Group Co., Ltd., and utpatinib extended-release tablets (Rinvoq®/瑞福®, 15 mg) owned by AbbVie Deutschland GmbH & Co. KG in healthy participants in China, under both fasting and postprandial conditions.
100 Clinical Results associated with Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.
Login to view more data
Login to view more data
100 Deals associated with Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.
Login to view more data
100 Translational Medicine associated with Heilongjiang Fuhe Huaxing Pharmaceutical Group Co. Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 31 Jul 2026
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
5
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free